Céline Pellaton
YOU?
Author Swipe
View article: Longitudinal characterisation of immune responses in blood and breast milk and symptoms after mRNA vaccination in lactating women
Longitudinal characterisation of immune responses in blood and breast milk and symptoms after mRNA vaccination in lactating women Open
BACKGROUND: Pregnant and lactating women were systematically excluded from the first SARS-CoV-2 vaccine trials, leading to great uncertainty in those women and their treating clinicians concerning the safety of the SARS-CoV-2 vaccine [1]. …
View article: Assessing the Value of T cell Monitoring in the General Population of Children and Adolescents – Insights From the Ciao Corona Cohort Study
Assessing the Value of T cell Monitoring in the General Population of Children and Adolescents – Insights From the Ciao Corona Cohort Study Open
Objectives Serological monitoring of SARS-CoV-2 antibodies in children and adolescents has been crucial for pandemic surveillance and response, while the role of T cell response monitoring remains uncertain. This study aimed to assess the …
View article: Features of chronic urticaria after COVID-19 mRNA vaccine over time
Features of chronic urticaria after COVID-19 mRNA vaccine over time Open
View article: Features of chronic urticaria after COVID-19 mRNA vaccine, a real-life cohort study
Features of chronic urticaria after COVID-19 mRNA vaccine, a real-life cohort study Open
Background New onsets of chronic urticaria (CU) have been reported after repeated immunizations, mainly with the Moderna mRNA-1273 vaccine (Spikevax) Objective This study aims to evaluate patients with CU after COVID-19 mRNA vaccination. T…
View article: Low plasma zinc levels (but not selenium) are associated with anti-SARS-COV-2 IGG and IGA seropositivity in the general population: A case-control study
Low plasma zinc levels (but not selenium) are associated with anti-SARS-COV-2 IGG and IGA seropositivity in the general population: A case-control study Open
View article: Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study
Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study Open
View article: Development of hybrid immunity during a period of high incidence of Omicron infections
Development of hybrid immunity during a period of high incidence of Omicron infections Open
Background Seroprevalence and the proportion of people with neutralizing activity (functional immunity) against SARS-CoV-2 variants were high in early 2022. In this prospective, population- based, multi-region cohort study, we assessed the…
View article: Persistent humoral immunity in children and adolescents throughout the COVID-19 pandemic (June 2020 to July 2022): a prospective school-based cohort study (Ciao Corona) in Switzerland
Persistent humoral immunity in children and adolescents throughout the COVID-19 pandemic (June 2020 to July 2022): a prospective school-based cohort study (Ciao Corona) in Switzerland Open
Objectives To assess the longitudinal development of humoral immunity in children and adolescents during the COVID-19 pandemic, with a particular focus on how anti-spike IgG antibodies and neutralising response changed during the first Omi…
View article: Association of plasma zinc levels with anti-SARS-CoV-2 IgG and IgA seropositivity in the general population: A case–control study
Association of plasma zinc levels with anti-SARS-CoV-2 IgG and IgA seropositivity in the general population: A case–control study Open
View article: CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses
CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses Open
A better understanding of the immunological markers associated with long-lasting immune responses to SARS-CoV-2 infection is of paramount importance. In the present study, we characterized SARS-CoV-2-specific humoral responses in hospitali…
View article: SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection
SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection Open
View article: Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study
Development of hybrid immunity during a period of high incidence of infections with Omicron subvariants: A prospective population based multi-region cohort study Open
Background Seroprevalence and the proportion of people with neutralizing activity against SARS-CoV-2 variants was high in early 2022. Since it is unclear how immunity in the general population evolves, the aim of this study was to assess t…
View article: Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients Open
Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regim…
View article: Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort
Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort Open
View article: Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022
Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022 Open
Functional immunity (defined here as serum neutralising capacity) critically contributes to conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross-sectional analysis of a prospective, population-based cohort stu…
View article: Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys Open
View article: SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties
SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties Open
The SARS-CoV-2 Omicron variant exhibits very high levels of transmission, pronounced resistance to authorized therapeutic human monoclonal antibodies and reduced sensitivity to vaccine-induced immunity. Here we describe P2G3, a human monoc…
View article: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients Open
This comparative effectiveness study suggests that approximately half of patients with hematologic cancers and solid cancers, about 70% of patients with solid organ transplants or autoimmune diseases, and 40% of healthy controls have lost …
View article: Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2 Infection: Compensatory Responses in a Population-Based Cohort
Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2 Infection: Compensatory Responses in a Population-Based Cohort Open
To better understand the development of immunity against SARS-CoV-2 over time, we evaluated humoral and cellular responses a population-based cohort of SARS-CoV-2-infected individuals covering the full spectrum of COVID-19 up to 217 days a…
View article: A highly potent antibody effective against SARS-CoV-2 variants of concern
A highly potent antibody effective against SARS-CoV-2 variants of concern Open
View article: A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma Open
A multiplexed virus-free surrogate neutralization assay measures antibody responses against spike protein mutations in SARS-CoV-2 variants.
View article: Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery Open
In these times of COVID-19 pandemic, concern has been raised about the potential effects of SARS-CoV-2 infection on immunocompromised patients, particularly on those receiving B-cell depleting agents and having therefore a severely depress…
View article: A multiplexed high-throughput neutralization assay reveals a lack of activity against multiple variants after SARS-CoV-2 infection
A multiplexed high-throughput neutralization assay reveals a lack of activity against multiple variants after SARS-CoV-2 infection Open
The detection of SARS-CoV-2-specific antibodies in the serum of an individual indicates prior infection or vaccination. However, it provides limited insight into the protective nature of this immune response. Neutralizing antibodies recogn…
View article: A Highly Potent Antibody Effective Against SARS-CoV-2 Variants of Concern
A Highly Potent Antibody Effective Against SARS-CoV-2 Variants of Concern Open
View article: Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies
Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies Open
In the present study, we have determined SARS-CoV-2-specific antibody responses in sera of acute and postinfection phase subjects. Our results indicate that antibody responses against viral S and N proteins were equally sensitive in the ac…
View article: Stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma therapy with full clinical recovery
Stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma therapy with full clinical recovery Open
Convalescent plasma to treat coronavirus disease 2019 (COVID-19) is currently the focus of numerous clinical trials worldwide, but the criteria of treatment efficacy remain largely unknown. Here, we describe a severely immunosuppressed pat…
View article: Changes in SARS-CoV-2 Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies
Changes in SARS-CoV-2 Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies Open
We have determined SARS-CoV-2-specific antibody responses in a cohort of 96 individuals with acute infection and in 578 individuals enrolled in a seroprevalence population study in Switzerland including three groups, i.e. subjects with pre…
View article: Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway
Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway Open
Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and nivolumab, act through blockade of the PD-1–PDL-1 interaction. Here, we have identified novel antagonistic anti–PD-1 Abs not blocking the PD-1–PDL-1 interact…
View article: Kinetic of CD160 or PD-1 expression on CD8 T cells stimulated upon T-cell stimulation.
Kinetic of CD160 or PD-1 expression on CD8 T cells stimulated upon T-cell stimulation. Open
(A) Representative flow cytometric profile of CD160 and PD-1 expression on CD8 T cells after 0, 24, 48, 72 and 120 hours of stimulation with anti-CD3/anti-CD28 magnetic beads. CD8 T-cell proliferation was also measured by CFSE-based…
View article: Expression levels of perforin and granzyme B in CD8 T-cell subsets defined by the expression of 2B4, CD160 and PD-1.
Expression levels of perforin and granzyme B in CD8 T-cell subsets defined by the expression of 2B4, CD160 and PD-1. Open
CD8 T-cell responses were analyzed within six CD8 T-cell subsets defined by 2B4, CD160 and/or PD-1 expression. (A) Representative flow cytometric profiles of CD8 T cells expressing perforin and/or granzyme B ex vivo. (B)